127 APPLICABILITY AND PERFORMANCE OF HEART FAILURE PROGNOSTIC SCORES IN DILATED CARDIOMYOPATHY: THE EXPERIENCE OF AN ITALIAN REFERRAL CENTER FOR CARDIOMYOPATHIES

Abstract Background Many prognostic risk scores have been developed for ambulatory Heart Failure (HF) patients, but none of these has validated in Dilated Cardiomyopathy (DCM), that is a peculiar model HF. Aims To evaluate and compare the applicability performance major HF models large real-world population DCM patients Methods This was retrospective study including 784 consecutive non ischemic both inpatients outpatients, enrolled Muscle Disease Registry (HMDR) Trieste between January 2000 December 2017. The following designed to estimate 1- 3-year all-cause mortality were calculated each participant: CHARM (Candesartan Failure-Assessment Reduction Mortality), MAGGIC (Meta-analysis Global Group Chronic Failure), simplified-SHFM (Seattle Model), 3-CHF (Cardiac Comorbid Conditions), GISSI-HF (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico-Heart MECKI (Metabolic Exercise test data combined with Cardiac Kidney Indexes), Barcelona Bio-HF, Krakow score. Results During follow-up (5,83 ± 4,9 years) 191 (20% population) met primary composite endpoint (158 deaths, 30 heart transplantations 3 LVAD implants). Due high quote missing parameters, only four (MAGGIC, CHARM, simplified-SHFM) could be tested final statistical analysis. observed-to-predicted ratios suggested an overestimation by all scores. accuracy scales suboptimal (AUC 0.754) 0.720) scores, worse 0,677) 0,667) respectively providing best worst performance. Conclusions patients. need new precise tailored this disease considered.